TA-MUC1 elevation + EGFR expression	Colorectal Cancer	TA-MUC1 elevation + EGFR expression	Colorectal Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3
TA-MUC1 elevation + EGFR expression	Breast Cancer	TA-MUC1 elevation + EGFR expression	Breast Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3
TA-MUC1 elevation + EGFR expression	Head and Neck Cancer	TA-MUC1 elevation + EGFR expression	Head and Neck Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3
TA-MUC1 elevation + EGFR expression	Non Small Cell Lung Cancer	TA-MUC1 elevation + EGFR expression	Non Small Cell Lung Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3

TA-MUC1 elevation + EGFR expression

Associations